Wayne and Gladys Valley Tower
490 Illinois St. Topaz Rm (1st floor)
UCSF Mission Bay Campus
Sunil Suhas Solomon, MBBS PhD MPH
Professor of Medicine and Epidemiology in the Division of Infectious Diseases
Johns Hopkins University School of Medicine
Dr. Solomon is the Managing Trustee of the YR Gaitonde Medical Educational and Research Foundation in Chennai, India. He currently co-directs the Johns Hopkins Center for Infectious Diseases in India. He completed his medical training at the Sri Ramachandra Medical University in Chennai, India and received a Master of Public Health (MPH) and a doctorate in Epidemiology (PhD) from the Johns Hopkins University, USA. Dr. Solomon has been elected into the Phi Beta Kappa honors society for academic excellence and the Delta Omega Public Health honors society. His research is primarily focused on the epidemiology, clinical management and access to services for HIV and viral hepatitis among vulnerable populations such as people who inject drugs (PWID) and men who have sex with men (MSM). He serves as a Deputy Editor of the Journal of the International AIDS Society and an Associate Editor of Drug and Alcohol Dependence. He is also a member of the PWID and ART technical resource group of the National AIDS Control Organization, India. His team established one of the first comprehensive clinics for the transgender community and people who inject drugs in India. He currently serves as the co-Chair of the Substance Use Scientific Committee (SUSC) of the HIV Prevention Trials Network (HPTN). He served as the Protocol Chair of ACTG A5360 (MINMON), a ground-breaking global trial on the simplification of HCV treatment delivery and currently serves as the Protocol Chair of HPTN 103/PURPOSE-4, the first trial of long-acting antiretrovirals for PrEP among people who inject drugs. He was also awarded US $50 million PEPFAR/USAID to provide technical assistance to the National AIDS Program in India. He is also one of the only recipients of both the NIH Directors New Innovator Award (DP2) and the Pioneer Award (DP1), the Avenir and the Avant-Garde awards, from the National Institute on Drug Abuse.